Perrigo's third-quarter launch of private label Nexium24HR was primary contributor of $13m in new product sales in North America.
Perrigo Co. PLC says launching private label OTC Nexium24HR near the end of the third quarter was enough to help drive $13m in new product sales in North America but not enough to pull the division out of a 2% dip from the year-ago period in reported net sales.
Reported North American OTC drug and adult and infant formula sales during the July-September period were $599m as the firm lost $21m in sales from divesting its vitamin, mineral and
The generic of the Nexium24HR brand Pfizer Inc
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.
The International Council for Harmonisation has consolidated and modernized its existing stability guidelines into one document, and addressed modern stability testing approaches like modeling, bracketing, and matrixing.
While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.
The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.
Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.
Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.
